Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-15T16:33:22.407Z Has data issue: false hasContentIssue false
  • English
  • Français

Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study

Published online by Cambridge University Press:  23 March 2020

Y.S. Woo ,
J.E. Park ,
D.H. Kim ,
I.K. Sohn ,
T.Y. Hwang ,
Y.M. Park ,
D.I. Jon ,
J.H. Jeong ,
B.H. Yoon  and
W.M. Bahk
Y.S. Woo*
Affiliation:
Yeouido St. Mary's Hospital, psychiatry, Seoul, Republic of Korea
J.E. Park
Affiliation:
Keyo Hospital, Keyo Medical Foundation, psychiatry, Uiwang, Republic of Korea
D.H. Kim
Affiliation:
Chuncheon Scared Heart Hospital, psychiatry, Chuncheon, Republic of Korea
I.K. Sohn
Affiliation:
Keyo Hospital, Keyo Medical Foundation, psychiatry, Uiwang, Republic of Korea
T.Y. Hwang
Affiliation:
Yong-in Mental Hospital, psychiatry, Yong-in, Republic of Korea
Y.M. Park
Affiliation:
Ilsan Paik Hospital, psychiatry, Goyang, Republic of Korea
D.I. Jon
Affiliation:
Sacred Heart Hospital, psychiatry, Anyang, Republic of Korea
J.H. Jeong
Affiliation:
St. Vincent's Hospital, psychiatry, Suwon, Republic of Korea
B.H. Yoon
Affiliation:
Naju National Hospital, psychiatry, Naju, Republic of Korea
W.M. Bahk
Affiliation:
Yeouido St. Mary's Hospital, psychiatry, Seoul, Republic of Korea
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Evidences for antipsychotics augmentation for schizophrenic patients with suboptimal efficacy have been lacking although it has been widespread therapeutic strategy in clinical practice.

Objectives

The purpose of this study was to investigate the efficacy and tolerability of blonanserin augmentation with an atypical antipsychotics (AAPs) in schizophrenic patients.

Methods

A total of 100 patients with schizophrenia partially or completely unresponsive to treatment with an AAP recruited in this 12-week, open-label, non-comparative, multicenter study. Blonanserin was added to existing AAPs which were maintained during the study period. Efficacy was primarily evaluated using Positive and Negative Syndrome Scale (PANSS) at baseline, week 2, 4, 8, and 12. Predictors for PANSS response (≥ 20% reduction) was investigated.

Results

The PANSS total score was significantly decreased at 12 weeks after blonanserin augmentation (–21.0 ± 18.1, F = 105.849, P < 0.001). Response rate on PANSS at week 12 was 51.0%. Premature discontinuation was occurred in 17 patients (17.0%) and 4 patients among them discontinued the study due to adverse events. Nine patients experienced significant weight gain during the study. Response to blonanserin augmentation was associated with severe (PANSS > 85) baseline symptom (OR = 10.298, P = 0.007) and higher dose (> 600 mg/day of chlorpromazine equivalent dose) of existing AAPs (OR = 4.594, P = 0.014).

Conclusions

Blonanserin augmentation improved psychiatric symptoms of schizophrenic patients in cases of partial or non-responsive to an AAP treatment with favorable tolerability. Patients with severe symptom despite treatment with higher dose of AAP were benefited from this augmentation. These results suggested that blonanserin augmentation could be an effective strategy for specific patients with schizophrenia.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW440
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. s226
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.